Research programme: anti-C35 breast cancer antibodies - Vaccinex

Drug Profile

Research programme: anti-C35 breast cancer antibodies - Vaccinex

Alternative Names: C35 antibody; VX 35; VX-C35; VX35/anti-C35 antibody

Latest Information Update: 08 Oct 2015

Price : $50

At a glance

  • Originator Vaccinex
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants; NF-kappa B modulators; Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 08 Oct 2015 Discontinued - Preclinical for Breast cancer in USA (Parenteral)
  • 18 Oct 2012 VX35 is still in preclinical trials for Breast cancer in USA
  • 30 Jun 2004 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top